The cost of generic Yervoy, also known as ipilimumab, can be determined by considering the expiration of its patent and entering the market. Originally developed and marketed by Bristol-Myers Squibb (BMS), Yervoy was approved by the FDA in 2011 for the treatment of melanoma.

According to DrugPatentWatch.com [1], a patent granted to Bristol-Myers Squibb for ipilimumab expired in 2021 in the US. The patent expiration would generally allow generic versions of Yervoy to enter the market, potentially reducing the cost of the treatment.

However, it is worth noting that not all patents that expire lead to the immediate introduction of generic versions, due to various reasons such as litigation or regulatory hurdles.

If generic versions of Yervoy have entered the market, it is reasonable to assume that prices have decreased. However, the exact current cost of generic Yervoy is difficult to determine as prices can vary depending on the specific product, manufacturer, and location.

Generic versions of ipilimumab may not be exact replicas of the original product, but they may provide similar efficacy at reduced prices.

Sources:

[1] DrugPatentWatch. (n.d.). Ipilimumab (Yervoy).Retrieved from https://www.drugpatentreform.org/t/Ipilimumab(Yervoy)US_2021